Guangzhou Xiangxue

Xiangxue Pharmaceutical is a prominent Chinese healthcare company that integrates Traditional Chinese Medicine (TCM) with cutting-edge biotechnology. While historically known for its market-leading antiviral oral liquids and TCM products, the company has expanded significantly into precision medicine through its subsidiary, Xiangxue Life Sciences. Its core biotech focus is on T-cell receptor engineered T-cell (TCR-T) therapies, utilizing its proprietary HATac platform to target solid tumors. The company's lead candidate, TAEST16001, is one of the first TCR-T therapies to enter clinical trials in China. Xiangxue is publicly traded on the Shenzhen Stock Exchange and maintains a robust manufacturing and R&D infrastructure in Guangzhou.